Arbutus Biopharma Corp (29)

Browse by Contract Category

Contracts

Technology Transfer and Exclusive License Agreement, dated December 13, 2021, by and between the Company and Qilu Pharmaceutical Co., Ltd (Filed With SEC on March 3, 2022)
Form of Arbutus Biopharma Corporation Indemnity Agreement (Filed With SEC on March 3, 2022)
Arbutus Biopharma Corporation 2016 Omnibus Share and Incentive Plan, as supplemented and amended (Filed With SEC on June 1, 2021)
Arbutus Biopharma Corporation 2020 Employee Stock Purchase Plan (Filed With SEC on June 1, 2020)
Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 3, 2022)
Third Amendment to Cross License Agreement, dated December 9, 2021, by and between Genevant Sciences GmbH and Arbutus Biopharma Corporation (Filed With SEC on December 10, 2021)
Amendment No. 3 to the Open Market Sale AgreementSM, dated March 4, 2021, by and between Arbutus Biopharma Corporation and Jefferies LLC (Filed With SEC on March 4, 2021)
Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 4, 2021)
Amendment No. 2 to the Open Market Sale Agreement (Filed With SEC on August 7, 2020)
Second Amendment to Cross License Agreement, dated June 27, 2018, by and among the Company, Genevant Sciences Ltd. And Genevant Sciences GmbH (Filed With SEC on August 7, 2020)
First Amendment to Cross License Agreement, dated June 27, 2018, by and among the Company, Genevant Sciences Ltd. And Genevant Sciences GmbH (Filed With SEC on August 7, 2020)
Cross License Agreement, dated April 11, 2018, by and between the Company and Genevant Sciences Ltd (Filed With SEC on August 7, 2020)
Arbutus Biopharma Corporation 2016 Omnibus Share and Incentive Plan, as supplemented and amended (Filed With SEC on June 1, 2020)
Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 5, 2020)
Offer Letter, dated August 8, 2019, by and between Arbutus Biopharma Corporation and Andrew Cheng (Filed With SEC on November 6, 2019)
Form of Arbutus Biopharma Corporation Indemnity Agreement (Filed With SEC on November 6, 2019)
Option Agreement, dated June 24, by and between Arbutus Biopharma, Inc. and William H. Collier (Filed With SEC on August 5, 2019)
Form of Arbutus Biopharma Corporation Option Agreement (Filed With SEC on August 5, 2019)
Arbutus Biopharma Corporation 2016 Omnibus Share and Incentive Plan, as supplemented (Filed With SEC on August 5, 2019)
Purchase and Sale Agreement, dated July 2, 2019, by and between Arbutus Biopharma Corporation and OCM IP Healthcare Portfolio LP (Filed With SEC on August 5, 2019)
Executive Employment Agreement, dated July 10, 2015, by and between Arbutus Biopharma, Inc. and Michael McElhaugh, as amended by the First Amendment to Executive Employment... (Filed With SEC on August 5, 2019)
Form of Indemnity Agreement (Filed With SEC on June 18, 2019)
Employment Agreement, dated June 13, 2019, by and between Arbutus Biopharma Corporation and William H. Collier (Filed With SEC on June 18, 2019)
Consulting Agreement, dated June 13, 2019, by and between Arbutus Biopharma, Inc. and Mark J. Murray (Filed With SEC on June 18, 2019)
Separation Agreement and Release, dated June 13, 2019, by and between Arbutus Biopharma Corporation and Mark J. Murray (Filed With SEC on June 18, 2019)
Koert VandenEnden Termination and Severance Agreement (Filed With SEC on May 6, 2019)
Executive Employment Agreement, dated June 11, 2018, by and between the Company and David Hasting (Filed With SEC on March 7, 2019)
Executive Signing Bonus, dated May 28, 2018, by and between the Company and David Hasting (Filed With SEC on March 7, 2019)
Form of Indemnity Agreement (re with initial Agreement by reference to Exhibit 4.15 to the Registrants Annual Report on Form 20-F for the year ended December 31, 2010 filed with... (Filed With SEC on March 7, 2019)